Evoke Pharma Reports Third Quarter 2016 Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Evoke Pharma Reports Third Quarter 2016 Results

Evoke Pharma (EVOK) Misses Q3 EPS by 3c

November 9, 2016 4:16 PM EST

Evoke Pharma (NASDAQ: EVOK) reported Q3 EPS of ($0.29), $0.03 worse than the analyst estimate of ($0.26).

Dave Gonyer, R.Ph., President and CEO, stated, The third quarter was a very active time for Evoke. After receiving results from our Phase 3 clinical trial of Gimoti for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women, we began extensive data analysis to better understand the outcome. We also completed a pre-New Drug Application... More